Overview

Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, counseling, and cessation resources (i.e., links to text-based support, self-change booklet). Varenicline helps to reduce cravings for tobacco use and decreases the pleasurable effects of cigarettes and other tobacco products.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Varenicline